Factors Associating Reluctance to Initiate or Continue Oral Antihyperglycemic Agent (OAHA) Treatments in Type 2 Diabetes Mellitus Patients in Japan: Observational, Cross-sectional, Patient-Reported and Web-Based Survey

Factors Associating Reluctance to Initiate or Continue Oral Antihyperglycemic Agent (OAHA) Treatments in Type 2 Diabetes Mellitus Patients in Japan: Observational, Cross-sectional, Patient-Reported and Web-Based Survey - Factors Associating Reluctance to Initiate or Continue Oral Antihyperglycemic Agent (OAHA) Treatments in Type 2 Diabetes Mellitus Patients in Japan: Observational, Cross-sectional, Patient-Reported and Web-Based Survey

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000026086

Enrollment

625

Registered

2017-02-18

Start date

2017-02-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients age 20+ Patients who receive healthcare in Japan Patients must self-report being either: 1.Diagnosed T2DM and have seen physician in past 6 months, recommended D&E, but not started any treatment for T2DM including OAHA, 2.Suspected T2DM patients who have seen a physician in the past 6 months and were recommended D&E due to their high blood glucose/HbA1c, but have not started any treatment for T2DM including OAHA, 3.Diagnosed T2DM patients who have seen a physician in the past 6 months are currently on OAHA monotherapy, and 4.Diagnosed T2DM patients who initiated OAHA treatment but then discontinued (patient reported basis) Able to read and understand Japanese and provide informed consent

Exclusion criteria

Exclusion criteria: Diagnosed with Type 1 Diabetes Mellitus Pregnant Drug-induced T2DM (Above listed 1 & 2) told by physician already being well-controlled on their glycemic levels and currently no need to engage in D&E therapy

Design outcomes

Primary

Measure	Time frame
Questionnaire items for barriers to T2DM treatment initiation in drug-naive T2DM group and continuation or adherence for non drug-naive T2DM group.	—

Countries

Japan

Contacts

Public ContactTakekazu Kubo

MSD K.K. Medical Affairs

ldgproject@merck.com03-6272-1000

Outcome results